Most people with hereditary angioedema (HAE) who received a single, 50 mg dose of lonvoguran ziclumeran, also called lonvo-z and formerly known as NTLA-2002, in a clinical trial have remained free from swelling attacks and no longer require long-term preventive therapy up to three years of follow-up. That’s according…
A young man in Greece developed acquired angioedema, one of the rarest forms of angioedema, as a complication of Mycoplasma pneumoniae infection — the bacterium best known for causing lung infection, or pneumonia — according to a recent case report. While being treated for pneumonia, the man suddenly…
People with type 2 diabetes who use DPP4 inhibitors to manage their disease do not seem to have a higher risk of developing angioedema compared with those taking other oral antidiabetic medications. That’s according to a study in South Korea, which found that new cases of angioedema occurred at…
Orladeyo (berotralstat) is now approved for reimbursement in the Netherlands following a recommendation from healthcare government agency Zorginstituut Nederland. The treatment is used for routine prevention, or prophylaxis, of swelling attacks in people 12 years and older with hereditary angioedema (HAE). With this decision,…
Get regular updates to your inbox.
